23andMe, Inc., a leading consumer genetics and research company, and VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by Virgin Group, announced Wednesday the completion of their previously announced business combination. The transaction uniquely positions 23andMe to revolutionize personalized healthcare and therapeutic development through human genetics. The combined company is called 23andMe Holding Co. and will be traded on The Nasdaq Global Select Market (“Nasdaq”) beginning on June 17, 2021 under the new ticker symbol “ME” for its Class A Common shares and “MEUSW” for its public warrants.
Avalon GloboCare Corp. (NASDAQ: AVCO) (“Avalon” or “the Company”), a clinical-stage global developer of cell-based technologies and therapeutics, announced that it has entered into a definitive agreement to acquire Hebei Senlang Biotechnology Co. Ltd. (“SenlangBio”), a PRC limited liability company. SenlangBio is currently the largest cell therapy company in Northern China in terms of bio-manufacturing scale, breadth and depth of clinical development programs, and pre-clinical research.
Elanco Animal Health Incorporated (NYSE: ELAN) and Kindred Biosciences, Inc. (KindredBio,NASDAQ: KIN) today announced the parties have entered into a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics based on validated human targets. The acquisition further accelerates Elanco’s expansion in the attractive pet health market, particularly advancing Elanco’s presence in the fast-growing billion-dollar dermatology category.
Calibre Scientific is pleased to announce the acquisition of LINARIS Biologische Produkte GmbH (“LINARIS”), a life science distributor with headquarters outside of Frankfurt, Germany. LINARIS will be integrated with BIOZOL Diagnostica GmbH, a subsidiary of Calibre Scientific, enhancing its sales capabilities and product range for customers in the DACH region. LINARIS is a specialized distributor of a comprehensive product offering that includes antibodies, proteins, ELISA kits, and reagents from leading global manufacturers.
AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the acquisition of Totient, a discovery company harnessing human immune responses to identify novel antibodies and their therapeutic targets. This acquisition adds antibody and target discovery technology to AbSci’s platform for therapeutic protein design and biomanufacturing optimization.
Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced it has executed a non-binding letter of intent (“LOI”) to acquire Novellus Therapeutics (“Novellus”), a company developing next-generation engineered mesenchymal stem cell (“MSC”) therapies using patented mRNA cell reprogramming and gene editing technologies licensed from Factor Bioscience (“Factor”).
VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by Virgin Group (“VGAC” or the “Company”) announced Thursday that its shareholders voted to approve the previously announced merger agreement with 23andMe, Inc. (“23andMe”) at VGAC’s extraordinary general meeting of shareholders (the “Special Meeting”) held earlier Thursday. The consummation of the business combination with 23andMe is expected to occur on June 16, 2021, subject to the satisfaction of customary closing conditions.
Clinical-trial sponsors are continually seeking to make clinical trials faster and to improve the experience for patients and physicians. Trial decentralization has emerged as a critical tool in this pursuit. It involves bringing an increasing proportion of a trial’s activities to the patients rather than using the traditional paradigm of bringing patients to a trial site. The COVID-19 pandemic has significantly catalyzed the adoption of decentralized clinical trials, with an increase in trial activities conducted remotely and in participants’ homes.
Valo Health LLC, an early-stage company focused on drug discovery and development, is going public through a combination with a special-purpose acquisition company, a deal that values the combined entity at about $2.8 billion, the companies said. Boston-based Valo and the SPAC, Khosla Ventures Acquisition Co. , said they expect to use proceeds from the transaction to help Valo develop its software platform and advance its preclinical and clinical drug pipeline. Valo was founded in 2019 by Flagship Pioneering, the Cambridge, Mass.-based venture-capital company that also has a stake in Covid-19 vaccine developer Moderna Inc.
Delic Holdings Inc. (“DELIC” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has signed a definitive agreement (the “Agreement”) to acquire Ketamine Infusion Centers LLC (“KIC”). KIC is a limited liability corporation formed under the laws of Arizona, which owns and operates two ketamine infusion treatment clinics, one in Phoenix, Arizona and the other in Bakersfield, California (the “Transaction”). Supported by clinical trials and peer reviewed studies, ketamine infusions have emerged as a promising treatment option for chronic diseases and pain disorders.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.